Picture of Mayne Pharma logo

MYX Mayne Pharma Cashflow Statement

0.000.00%
au flag iconLast trade - 00:00
HealthcareAdventurousSmall CapNeutral

Annual cashflow statement for Mayne Pharma, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.

2020
June 30th
2021
June 30th
2022
June 30th
2023
June 30th
2024
June 30th
Period Length:12 M12 M12 M12 M12 M
Source:ARSARSARSARSARS
Standards:
IFRS
IFRS
IFRS
IFRS
IFRS
Status:FinalFinalFinalFinalFinal
Changes in Working Capital-30.4-22.2-32.3-38.9-2.65
Other Operating Cash Flow
Cash from Operating Activities99.858.9-7.21-42.7-15.3
Capital Expenditures-47.1-25.1-11.9-220-20.9
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items-8.76-24.1-16.769374.3
Acquisition of Business
Sale of Business
Sale of Fixed Assets
Sale/Maturity of Investment
Change in Net Investments
Purchase of Investments
Other Investing Cash Flow
Cash from Investing Activities-55.9-49.2-28.547353.4
Financing Cash Flow Items-11.6-9.41-4.815.75
Other Financing Cash Flow
Total Cash Dividends Paid
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities4.52-40.427.6-432-19.9
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash48.8-39.8-1.31-4.0617.5